Compare VZ & ABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VZ | ABT |
|---|---|---|
| Founded | 1983 | 1888 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.9B | 222.8B |
| IPO Year | 2000 | N/A |
| Metric | VZ | ABT |
|---|---|---|
| Price | $39.53 | $107.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 17 |
| Target Price | $47.92 | ★ $147.24 |
| AVG Volume (30 Days) | ★ 25.6M | 7.8M |
| Earning Date | 01-30-2026 | 01-22-2026 |
| Dividend Yield | ★ 6.99% | 2.32% |
| EPS Growth | ★ 102.83 | N/A |
| EPS | ★ 4.69 | 3.72 |
| Revenue | ★ $137,491,000,000.00 | $44,328,000,000.00 |
| Revenue This Year | $5.39 | $9.93 |
| Revenue Next Year | $1.82 | $7.62 |
| P/E Ratio | ★ $8.42 | $29.20 |
| Revenue Growth | 2.42 | ★ 5.67 |
| 52 Week Low | $10.60 | $105.78 |
| 52 Week High | $47.36 | $141.23 |
| Indicator | VZ | ABT |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 17.11 |
| Support Level | $38.68 | $105.78 |
| Resistance Level | $39.69 | $122.49 |
| Average True Range (ATR) | 0.59 | 2.83 |
| MACD | -0.05 | -1.78 |
| Stochastic Oscillator | 37.03 | 8.45 |
Wireless services account for 75% of Verizon Communications' total service revenue and nearly all of its operating income. The firm serves about 93 million postpaid and 20 million prepaid phone customers via its nationwide network, making it the largest US wireless carrier. Fixed-line telecom operations include local networks in the Northeast that reach about 30 million homes and businesses, including about 20 million with the Fios fiber optic network. These networks serve about 8 million broadband customers. Verizon also provides telecom services nationwide to enterprise customers, often using a mixture of its own and other carriers' networks. Verizon agreed to acquire Frontier Communications in September 2024.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.